D
Inhibikase Therapeutics, Inc.
IKT
$2.36
$0.114.89%
D
Sell
12/30/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 12/30/2024 due to a noticeable increase in the total return index, volatility index and valuation index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 12/30/2024 due to a noticeable increase in the total return index, volatility index and valuation index.
E
Sell
11/12/2024Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 11/12/2024 due to a decline in the valuation index, volatility index and growth index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 11/12/2024 due to a decline in the valuation index, volatility index and growth index.
D
Sell
10/28/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 10/28/2024 due to an increase in the volatility index and total return index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 10/28/2024 due to an increase in the volatility index and total return index.
E
Sell
10/10/2024Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and valuation index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and valuation index.
D
Sell
9/25/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index and valuation index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index and valuation index.
E
Sell
9/5/2024Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 9/5/2024 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 9/5/2024 due to a decline in the volatility index.
D
Sell
8/20/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 8/20/2024 due to an increase in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 8/20/2024 due to an increase in the volatility index.
E
Sell
5/30/2024Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 5/30/2024 due to a decline in the volatility index, total return index and valuation index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 5/30/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/14/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 5/14/2024 due to an increase in the volatility index and valuation index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 5/14/2024 due to an increase in the volatility index and valuation index.
E
Sell
4/29/2024Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 4/29/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.01 to 0.05, and the quick ratio declined from 6.14 to 3.85.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 4/29/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.01 to 0.05, and the quick ratio declined from 6.14 to 3.85.
D
Sell
3/20/2024Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 3/20/2024 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 23.11% from -$6.2M to -$4.77M, earnings per share increased from -$1.1056 to -$0.8601, and operating cash flow increased 10.08% from -$4.57M to -$4.11M.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 3/20/2024 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 23.11% from -$6.2M to -$4.77M, earnings per share increased from -$1.1056 to -$0.8601, and operating cash flow increased 10.08% from -$4.57M to -$4.11M.
E
Sell
10/30/2023Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to E+ from E on 10/30/2023 due to an increase in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to E+ from E on 10/30/2023 due to an increase in the volatility index.
E
Sell
10/13/2023Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E from E+ on 10/13/2023 due to a decline in the volatility index and growth index. EBIT declined 31.55% from -$4.71M to -$6.2M, and earnings per share declined from -$0.9766 to -$1.1056.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E from E+ on 10/13/2023 due to a decline in the volatility index and growth index. EBIT declined 31.55% from -$4.71M to -$6.2M, and earnings per share declined from -$0.9766 to -$1.1056.
E
Sell
3/14/2023Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 03/14/2023.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/27/2023Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 2/27/2023 due to an increase in the volatility index and total return index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 2/27/2023 due to an increase in the volatility index and total return index.
E
Sell
2/9/2023Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 2/9/2023 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 2/9/2023 due to a decline in the volatility index.
D
Sell
1/25/2023Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 1/25/2023 due to an increase in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 1/25/2023 due to an increase in the volatility index.
E
Sell
1/10/2023Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index.
D
Sell
12/22/2022Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 12/22/2022 due to an increase in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 12/22/2022 due to an increase in the volatility index.
E
Sell
12/7/2022Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 12/7/2022 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 12/7/2022 due to a decline in the volatility index.
D
Sell
11/21/2022Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 11/21/2022 due to a noticeable increase in the growth index, solvency index and volatility index. The quick ratio increased from 7.18 to 8.26, total revenue increased 10.61% from $6.6 to $7.3, and earnings per share increased from -$0.1839 to -$0.1782.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 11/21/2022 due to a noticeable increase in the growth index, solvency index and volatility index. The quick ratio increased from 7.18 to 8.26, total revenue increased 10.61% from $6.6 to $7.3, and earnings per share increased from -$0.1839 to -$0.1782.
E
Sell
8/15/2022Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 8/15/2022 due to a large decline in the growth index and solvency index. Total revenue declined 85.65% from $46 to $6.6, the quick ratio declined from 8.37 to 7.18, and operating cash flow declined 10.72% from -$3.93M to -$4.36M.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 8/15/2022 due to a large decline in the growth index and solvency index. Total revenue declined 85.65% from $46 to $6.6, the quick ratio declined from 8.37 to 7.18, and operating cash flow declined 10.72% from -$3.93M to -$4.36M.
D
Sell
5/20/2022Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 5/20/2022 due to an increase in the growth index and volatility index. Total revenue increased 2,321.05% from $1.9 to $46, EBIT increased 7.95% from -$5.04M to -$4.64M, and earnings per share increased from -$0.1998 to -$0.1841.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 5/20/2022 due to an increase in the growth index and volatility index. Total revenue increased 2,321.05% from $1.9 to $46, EBIT increased 7.95% from -$5.04M to -$4.64M, and earnings per share increased from -$0.1998 to -$0.1841.
E
Sell
5/6/2022Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 5/6/2022 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 5/6/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 4/21/2022 due to an increase in the volatility index and growth index.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 4/21/2022 due to an increase in the volatility index and growth index.
E
Sell
3/25/2022Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 3/25/2022 due to a decline in the volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 3/25/2022 due to a decline in the volatility index.
D
Sell
11/17/2021Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 11/17/2021.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E+ on 11/17/2021.
E
Sell
11/8/2021Downgrade
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
9/1/2021Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 2.77 to 24.79, and debt to equity declined from 0.15 to 0.01.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to D- from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 2.77 to 24.79, and debt to equity declined from 0.15 to 0.01.
E
Sell
6/1/2021Upgraded
Inhibikase Therapeutics, Inc. (IKT) was upgraded to E from E- on 6/1/2021 due to a significant increase in the solvency index, growth index and total return index. Total revenue increased 725.82% from $170.4 to $1.41M.
Inhibikase Therapeutics, Inc. (IKT) was upgraded to E from E- on 6/1/2021 due to a significant increase in the solvency index, growth index and total return index. Total revenue increased 725.82% from $170.4 to $1.41M.
E
Sell
3/19/2021None
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E- from U on 03/19/2021.
Inhibikase Therapeutics, Inc. (IKT) was downgraded to E- from U on 03/19/2021.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
